BRIEF COMMUNICATION

Factor IX mutations in Haemophilia B patients in Malaysia: a preliminary study


Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia and *National Blood Centre, Kuala Lumpur, Malaysia

Abstract

Haemophilia B is caused by coagulation defects in the factor IX gene located in Xq27.1 on the X chromosome. Identification of mutations contributing to defective factor IX may be advantageous for precise carrier and prenatal diagnosis. We studied 16 patients from 11 families, consisting of 8 patients of the Malay ethnic group, of which 6 were siblings. Factor IX mutations have not been previously reported in the Malay ethnic group. The functional region of the factor IX gene was sequenced and mutations were identified in either the exon or intronic regions in 15 of the patients. One novel mutation, 6660_6664delTTCTT was identified in siblings with moderate form of haemophilia B. Mutations identified in our patients when linked with disease severity were similar to findings in other populations. In summary, this preliminary data will be used to build a Malaysian mutation database which would facilitate genetic counseling.

Key words: factor IX, Hemophilia B, mutation, clotting factor

INTRODUCTION

Haemophilia B (HB) is an X-linked inherited blood clotting disorder resulting from deficiency in the blood coagulation factor IX. Deficiency of the clotting factor is caused by mutation of the Factor IX gene. The disease has been expressed in males and diagnosis is confirmed by low activity of plasma factor IX (FIX). Mutations of this gene have been curated in the Haemophilia B mutation database.1 The different mutations identified in factor IX have been found among patients with varying severity of HB. Patients with HB accounted for about 9% of patients with hereditary bleeding disorders in Malaysia.2 At present, there is a lack of information of mutations of this gene in Malaysian patients. This preliminary study aims to characterise mutations of the factor IX gene in HB patients from various ethnic groups in Malaysia.

MATERIALS AND METHODS

Our study was conducted on 16 patients (8 unrelated patients and 8 siblings from 4 families). Five families had only one affected male with HB. Informed consent was obtained from each family. The disease severity of the patients was determined by coagulation factor levels. Of the cases studied, 5 were classified as severe cases of HB while 11 had moderate form of HB.

Amplification and direct sequencing of the factor IX gene was carried out using previously published primers.3,4 Purification of amplicons was carried out using QIAquick PCR Purification Kit (Qiagen, Germany). Sequencing reactions using BigDye® Terminator v3.1 cycle Sequencing kit (Applied Biosystems, USA) were run on ABI 3130 Genetic Analyzer. Exons 1-8 of factor IX gene was sequenced in all patients, and where available, in the mothers of the patients. Factor IX sequence (Genbank Acc No: K02402) was used as a reference and mutations were numbered accordingly.5

RESULTS AND DISCUSSION

Mutations were identified in 15 patients with an exception of 1 patient with factor IX activity levels of 5% (Table 1). Mutations were identified at the promoter, conserved exon amino acids and the donor/acceptor splice sites. One novel
mutation was identified in this study. No factor IX inhibitors had been detected in the patients.

Promoter change 6T>A was identified in 2 brothers of Chinese origin with moderate severity of the disease. The males of family 1 (F1) were first diagnosed at 3 and 5 years of age. Their mother is a carrier with coagulation activity of 59.3%. Previous studies reported the mutation in 2 neonates with severe phenotype with increased levels of FIX coagulant activity on the onset of puberty as commonly seen in HB Leyden.6,7

Frameshift mutation 6365G>A (R-4Q) change in the CpG dinucleotide region was found in a Malay patient with severe HB. Donor splice site mutations, 6490G>A and 6707G>A were identified in patients with severe and moderate haemophilia B respectively. This findings concurs with a number of other studies.3,9 Novel intronic change 6660_6664delTTCTT (5bp) was found in 2 siblings of Malay origin with moderate phenotype. Mutation 6660_6664delTTCTT (5bp) was previously found to cause 2% of normal factor IX activity.8 Their mother is a carrier with heterozygous mutation.

17692G>A was found in siblings (H10 and H11) of Malay origin with severe form of HB. The patients’ mother is a carrier with low levels of plasma factor IX. Patient H16 with moderate phenotype carried the same mutation in HB, which was diagnosed in 3 generations. However, the mutation could not be tested in other patients within the family.  The mutation was previously described in severe and moderate cases.3,7

Double mutations and mutations in catalytic domain of the protein were not identified in our patients. This was probably due to the small sample size. In this study, we found that differences in disease severity could be linked with the type of mutation the patients. Information on factor IX antigen levels indicating the levels of the mutated protein present in the blood were not available. The patient in whom no mutation was detected could have had mutations in the intronic sequences and the region upstream to promoter. This preliminary study reports a part

<table>
<thead>
<tr>
<th>Patient</th>
<th>Factor IX activity (%)</th>
<th>Region</th>
<th>Mutation</th>
<th>Affected amino acid</th>
<th>Ethnic group</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>H8= 4.0</td>
<td>promoter</td>
<td>6T&gt;A</td>
<td></td>
<td>Chinese</td>
</tr>
<tr>
<td>F2</td>
<td>H5=1.8</td>
<td>exon 2</td>
<td>6460C&gt;T</td>
<td>R29X</td>
<td>Malay</td>
</tr>
<tr>
<td>F3</td>
<td>H12=1.35</td>
<td>intron 2</td>
<td>6660-6664delTTCTT</td>
<td></td>
<td>Malay</td>
</tr>
<tr>
<td>F4</td>
<td>H10=&lt;1.0</td>
<td>exon 5</td>
<td>17692 G&gt;A</td>
<td>G93S</td>
<td>Malay</td>
</tr>
<tr>
<td>F5</td>
<td>H3=&lt;1.0</td>
<td>exon 2</td>
<td>6365G&gt;A</td>
<td>R-4Q</td>
<td>Malay</td>
</tr>
<tr>
<td>F6</td>
<td>H4=&lt;1.0</td>
<td>exon 2</td>
<td>6396_6397delAG frameshift</td>
<td></td>
<td>Chinese</td>
</tr>
<tr>
<td>F7</td>
<td>H1= &lt;1.0</td>
<td>intron 2</td>
<td>6690G&gt;A</td>
<td></td>
<td>Indian</td>
</tr>
<tr>
<td>F8</td>
<td>H15=1.78</td>
<td>intron 3</td>
<td>6707G&gt;A</td>
<td></td>
<td>Chinese</td>
</tr>
<tr>
<td>F9</td>
<td>H16=1.5</td>
<td>exon 5</td>
<td>17692G&gt;A</td>
<td>G93S</td>
<td>Malay</td>
</tr>
<tr>
<td>F10</td>
<td>H2=&lt;1.0</td>
<td>exon 6</td>
<td>20540C&gt;A</td>
<td>A187D</td>
<td>Chinese</td>
</tr>
<tr>
<td>F11</td>
<td>H7=2.5</td>
<td>exon 6</td>
<td>20540C&gt;A</td>
<td>A187D</td>
<td>Chinese</td>
</tr>
</tbody>
</table>
of the factor IX mutations found in the different ethnic groups in Malaysia. Further studies on the mutation spectra of the HB cases in Malaysia would be useful.

ACKNOWLEDGEMENTS

The project was funded by the Ministry of Science, Technology and Environment, Malaysia. The authors thank the Director General of Health of Malaysia for permission to publish this article and the Director of the Institute for Medical Research for her support. The authors thank Huraizah Sidek, Hanisah Sabri, other staff and trainees at the Molecular Pathology Unit and the staff of Haemostasis and Thrombosis Laboratory, National Blood Centre for their technical assistance and support.

REFERENCES